# NMDA Receptor Antagonists in Pain Management

## Introduction

The N-methyl-D-aspartate (NMDA) receptor plays a pivotal role in central sensitization, wind-up phenomena, and the transition from acute to chronic pain. NMDA receptor antagonists — primarily ketamine and memantine — offer a unique mechanism-based approach to managing chronic pain conditions that are refractory to conventional therapies. Ketamine infusions have gained significant attention for complex regional pain syndrome (CRPS), neuropathic pain, and treatment-resistant chronic pain, though their use requires careful patient selection and safety monitoring.

## NMDA Receptor Physiology in Pain

NMDA receptors are ligand-gated, voltage-dependent ionotropic glutamate receptors found throughout the central nervous system, with particularly high density in the spinal dorsal horn. At resting membrane potential, the NMDA receptor channel is blocked by a magnesium ion. This block is relieved when sustained nociceptive input depolarizes the postsynaptic membrane, allowing calcium to flow into the cell.

This calcium influx triggers a cascade of intracellular signaling events: activation of protein kinase C (PKC) and calmodulin-dependent kinase II (CaMKII), upregulation of nitric oxide synthase, and phosphorylation of AMPA receptors that increases their membrane insertion. Together, these processes mediate central sensitization and wind-up — the progressive amplification of pain signaling with repeated stimulation. NMDA receptor activation is critical in the transition from acute nociceptive pain to chronic pain states, as well as in the development of opioid-induced hyperalgesia and opioid tolerance.

<image>Detailed molecular diagram of the NMDA receptor complex at the spinal dorsal horn synapse, showing the heterotetrameric structure with NR1 and NR2 subunits, the magnesium block at resting potential, glutamate and glycine co-agonist binding sites, the intracellular calcium signaling cascade leading to PKC activation and central sensitization, and the binding site of ketamine within the open channel pore acting as an open-channel blocker</image>

## Ketamine

### Pharmacology

Ketamine is a non-competitive open-channel blocker of the NMDA receptor — it enters the channel pore only when the receptor is in the open (activated) state. Beyond NMDA antagonism, ketamine has multiple additional mechanisms contributing to analgesia: weak agonism at mu and kappa opioid receptors, inhibition of serotonin, norepinephrine, and dopamine reuptake, modulation of cholinergic and sodium channel signaling, and facilitation of descending inhibitory pathways.

Ketamine is available as a racemic mixture or as the S(+)-ketamine enantiomer (esketamine), which has approximately four-fold higher NMDA receptor affinity. It is metabolized hepatically via CYP3A4 and CYP2B6 to norketamine, an active metabolite with about 30% of the parent compound's potency. The half-life of ketamine is 2-3 hours intravenously, while norketamine persists for about 12 hours.

### Evidence for CRPS

CRPS has the strongest evidence base for ketamine infusion therapy among chronic pain conditions. Multiple randomized controlled trials and systematic reviews support subanesthetic ketamine infusions for CRPS pain reduction, with 50-70% of patients achieving meaningful relief. The duration of benefit is variable, typically lasting weeks to months following an infusion series. The 2018 Cochrane review found low-to-moderate quality evidence supporting short-term benefit. The proposed mechanism involves disruption of the maladaptive central sensitization and neuroplasticity characteristic of CRPS, with potential reduction in allodynia, hyperalgesia, and autonomic features.

### Evidence for Neuropathic Pain

Moderate evidence supports short-term benefit in refractory neuropathic pain conditions including postherpetic neuralgia, phantom limb pain, and central pain syndromes. Intravenous ketamine produces rapid analgesic onset (within hours) compared to conventional neuropathic pain medications. Evidence for sustained benefit beyond the infusion period is less robust. Ketamine may be particularly useful in patients who have failed first-line neuropathic pain medications such as gabapentinoids, SNRIs, and TCAs.

### Evidence for Treatment-Resistant Pain

Emerging evidence supports ketamine's use in fibromyalgia, cancer pain with opioid tolerance, and chronic post-surgical pain. Ketamine may reverse opioid tolerance by resetting NMDA-mediated tolerance mechanisms and has a potential role in opioid-induced hyperalgesia (OIH) by blocking the central sensitization that paradoxically increases pain sensitivity. However, evidence remains limited by small sample sizes, heterogeneous protocols, and lack of long-term follow-up.

## Practical Ketamine Infusion Protocols

### Outpatient Subanesthetic Infusion

The standard outpatient approach uses a dose range of 0.1-0.5 mg/kg/hour intravenously over 4-6 hours. A typical protocol involves a series of 3-5 infusions over 1-2 weeks, sometimes with escalating doses across the series. The maximum recommended outpatient rate is 0.5 mg/kg/hour. Pre-infusion assessment should include vital signs, psychiatric screening, hepatic function, and urinalysis.

### Inpatient Intensive Protocol (for CRPS)

For severe, refractory CRPS, specialized centers may use higher doses of 0.5-2.0 mg/kg/hour for extended periods (hours to days), with some protocols extending to 4-5 day continuous infusions. These require continuous cardiac and respiratory monitoring and are reserved for specialized centers.

### Subcutaneous and Oral Routes

Subcutaneous infusion is an emerging route that allows outpatient or home administration. Oral ketamine has variable bioavailability (16-29%) and is used for maintenance therapy between infusions. Intranasal esketamine (Spravato) is FDA-approved for treatment-resistant depression but its use for pain remains off-label with limited evidence.

<image>Clinical protocol flowchart for ketamine infusion therapy in chronic pain, showing patient selection criteria (failed first-line therapies, no active psychosis, no uncontrolled hypertension), pre-infusion screening checklist, infusion day monitoring parameters (vital signs every 15 minutes, sedation scale, psychomimetic effects assessment), dose titration algorithm starting at 0.1 mg/kg/hr and escalating based on response and tolerance, post-infusion observation period, and discharge criteria with follow-up schedule</image>

## Safety Monitoring and Adverse Effects

### Acute Adverse Effects During Infusion

Psychomimetic effects — dissociation, vivid dreams, hallucinations, and derealization — are the most common treatment-limiting adverse effects and can be managed with benzodiazepines (midazolam 0.5-1 mg IV). Cardiovascular effects include hypertension and tachycardia from sympathomimetic stimulation, requiring continuous monitoring. Nausea is common and should be pretreated with ondansetron. Nystagmus and dizziness are dose-dependent. Laryngospasm is rare at subanesthetic doses but mandates emergency preparedness.

### Chronic Use Concerns

Urological toxicity is among the most serious long-term risks: interstitial cystitis, ulcerative cystitis, and bladder fibrosis can develop, with prevalence increasing with cumulative dose and frequency. Hepatotoxicity manifests as transient LFT elevations, requiring serial hepatic function monitoring. Long-term cognitive effects on memory and cognition remain uncertain. Ketamine is a Schedule III controlled substance and a known recreational drug of abuse, with psychological dependence possible after repeated therapeutic use.

### Contraindications

Absolute and relative contraindications include uncontrolled hypertension or cardiovascular disease, active psychosis or schizophrenia, elevated intracranial or intraocular pressure, pregnancy, active substance use disorder, and significant hepatic impairment.

## Memantine

### Pharmacology and Evidence

Memantine is a low-affinity, voltage-dependent NMDA receptor antagonist with faster unbinding kinetics than ketamine. It is FDA-approved for moderate-to-severe Alzheimer disease. Despite its theoretical analgesic potential based on NMDA blockade, clinical evidence for chronic pain has been largely disappointing. Systematic reviews show no consistent benefit for neuropathic pain, though some positive signals exist for phantom limb pain and CRPS at doses of 20-40 mg per day. Memantine is better tolerated than ketamine, with no psychomimetic effects, and may have a role in opioid tolerance prevention based on limited preclinical data. It is not recommended as a primary analgesic based on current evidence.

## Other NMDA Antagonists

| NMDA Antagonist | Affinity | Route | Key Pain Indication | Evidence Quality | Notes |
|----------------|----------|-------|-------------------|-----------------|-------|
| Ketamine | High (open-channel blocker) | IV, SC, oral, intranasal | CRPS, refractory neuropathic pain, OIH | Moderate | Schedule III; psychomimetic effects |
| Esketamine (S-ketamine) | ~4x higher than racemic | Intranasal (Spravato) | Treatment-resistant depression (FDA); pain off-label | Limited for pain | FDA-approved for depression only |
| Memantine | Low (voltage-dependent) | Oral | Phantom limb pain, CRPS (limited) | Poor | Better tolerated; no psychomimetic effects |
| Dextromethorphan | Low | Oral | Adjunct analgesic (limited) | Poor | Available OTC; Nuedexta for pseudobulbar affect |
| Magnesium | Physiological blocker | IV | Perioperative pain reduction | Moderate (perioperative) | Limited chronic pain data |
| Methadone | Moderate (non-competitive) | Oral, IV | Neuropathic pain, OIH | Moderate | Also a full mu-agonist + SNRI |

Several other compounds have NMDA antagonist properties with varying degrees of clinical relevance. Dextromethorphan is a low-affinity NMDA antagonist with limited evidence as an analgesic adjunct; its combination with quinidine (Nuedexta) is FDA-approved for pseudobulbar affect but not for pain. Intravenous magnesium, the physiological NMDA receptor blocker, has evidence for perioperative pain reduction but limited chronic pain data. Amantadine, a weak NMDA antagonist, has some evidence for surgical pain but not for chronic pain. Methadone is unique among opioids in also functioning as an NMDA antagonist, which may contribute to its particular efficacy in neuropathic pain and its utility in opioid rotation.

<image>Receptor binding comparison diagram showing ketamine, memantine, dextromethorphan, and magnesium at the NMDA receptor, illustrating their relative binding affinities, kinetics of channel block and unblock, and clinical implications of these pharmacodynamic differences, with a spectrum showing high-affinity long-duration block (ketamine) to low-affinity rapid unblock (memantine and magnesium)</image>

## Clinical Pearls

Ketamine's analgesic mechanism centers on open-channel NMDA receptor blockade, which disrupts central sensitization — it is most effective when central sensitization is a dominant pain driver. CRPS has the strongest evidence base for ketamine infusion therapy among chronic pain conditions, though long-term data remain limited. Psychomimetic effects are the most common treatment-limiting adverse effect, and pre-treatment with low-dose midazolam can mitigate these symptoms. Ketamine may be particularly valuable in patients with opioid tolerance or opioid-induced hyperalgesia, as NMDA blockade addresses the underlying sensitization mechanism. Urological monitoring (urinalysis and symptom questionnaire) should be performed in patients receiving repeated ketamine infusions due to the risk of interstitial cystitis. Memantine has not demonstrated reliable analgesic efficacy despite its NMDA antagonism — differences in binding kinetics and affinity likely explain its divergence from ketamine.

## References

1. Schwenk ES, Viscusi ER, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. *Reg Anesth Pain Med*. 2018;43(5):456-466.
2. Connolly SB, Prager JP, Harden RN. A systematic review of ketamine for complex regional pain syndrome. *Pain Med*. 2015;16(5):943-969.
3. Michelet D, Brasher C, Horlin AL, et al. Ketamine for chronic non-cancer pain: a meta-analysis and trial sequential analysis of randomized controlled trials. *Eur J Pain*. 2018;22(4):632-646.
4. Pickering G, Morel V, Simen E, et al. Oral magnesium treatment in patients with neuropathic pain: a randomized clinical trial. *Magnes Res*. 2011;24(2):28-35.